KRAS inhibitor-9

CAS No. 300809-71-6

KRAS inhibitor-9( DUN09716 )

Catalog No. M22747 CAS No. 300809-71-6

KRAS inhibitor-9 is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 139 In Stock
2MG 74 In Stock
5MG 116 In Stock
10MG 188 In Stock
25MG 353 In Stock
50MG 500 In Stock
100MG 642 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KRAS inhibitor-9
  • Note
    Research use only, not for human use.
  • Brief Description
    KRAS inhibitor-9 is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS.
  • Description
    KRAS inhibitor-9 is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells
  • In Vitro
    KRAS inhibitor-9 bound to KRASG12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity of -5.38, -5.41, and -3.97 kcal/mol, respectively. KRAS inhibitor-9 (0-100 μM) shows strong inhibition selectivity in NSCLC cells with IC50s ranging from 39.56 to 66.02 μM for H2122, H358 and H460 cells (at 72 hours).KRAS inhibitor-9 (0-100 μM; 24 hours) blocks GTP-KRAS formation in H2122, H358 and H460 cells.KRAS inhibitor-9 (25-100 μM; 48 hours) inhibits the activation of KRAS downstream signaling pathway.KRAS inhibitor-9 (0-100 μM; 24-72 hours) induces cell cycle arrest and apoptosis in NSCLC. Cell Viability Assay Cell Line:H2122 (KRAS G12C), H358 (KRAS G12C) and H460 (KRAS Q61H) cell lines Concentration:0, 25, 50, 100 μM Incubation Time:24, 48, and 72 hoursResult:Inhibited three NSCLC cell lines in a dose- and time-dependent manner, but not in normal lung fibroblast cell line CCD-19Lu.Western Blot Analysis Cell Line:H2122, H358 and H460 cells Concentration:0, 25, 50, 100 μM Incubation Time:48 hours Result:Reduces the levels of phosphorylation of CRAF and AKT in a dose-dependent manner in H2122, H358 and H460 cells.Apoptosis Analysis Cell Line:H2122, H358, H460 cellsConcentration:0, 25, 50, 100 μM Incubation Time:24-72 hours Result:Significantly decreased in G0/G1 phase while remarkably increased in G2/M phase after 24 hours and induced a significantly increased apoptosis for 48h in NSCLC cell lines.
  • In Vivo
    ——
  • Synonyms
    DUN09716
  • Pathway
    MAPK/ERK Signaling
  • Target
    Ras
  • Recptor
    KRAS
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    300809-71-6
  • Formula Weight
    292.8
  • Molecular Formula
    C13H9ClN2S2?
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:230 mg/mL?(785.49 mM;?Need ultrasonic)
  • SMILES
    Nc1ccc(Sc2nc3ccccc3s2)c(Cl)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Xie C, et al. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol. 2017;8:823. Published 2017 Nov 14.
molnova catalog
related products
  • pan-Ras inhibitor 31...

    pan-Ras inhibitor 3144 (Compound 3144) is a multivalent small-molecule, pan-RAS inhibitor.

  • SAH-SOS1A

    KRas/son of sevenless 1 (SOS1) interaction inhibitor. Binds within nucleotide binding pocket of KRas (Kd values are 106 - 176 nM for wild type KRas and various KRas mutants). Inhibits nucleotide binding to KRas in a concentration dependent manner. Displays cytotoxicity in KRas-driven cancer cell lines and inhibits downstream ERK-MAPK signaling. Cell permeable.

  • K-Ras G12C-IN-4

    K-Ras G12C-IN-4 is a potent co-valent Inhibitor of KRAS G12C.